MedTrace Logo

AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

NCT01018550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 397

Last updated 2016-03-23

No results posted yet for this study

Summary

The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.

Conditions

Interventions

DRUG

AMG 853

AMG 853 5 mg (BID)

DRUG

AMG 853

AMG 853 200 mg (QD)

DRUG

AMG 853

AMG 853 25 mg (BID)

DRUG

AMG 853

AMG 853 100 mg (BID)

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-12-31
Completion
2011-03-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018550 on ClinicalTrials.gov